Search clinical trials for: Sodium Glucose Co-transporter 2 inhibitor

Total 118612 results

Jeil Pharmaceutical Co., Ltd.

Not yet recruiting

Evaluation of Efficacy and Safety When Administered JP-2266 in Type 2 Diabetes Patients

Type 2 Diabetes Mellitus

Korea, Republic of
Xiangya Hospital of Central South University

Recruiting

Efficacy and Safety Of Different Regimens In Patients With Type 2 Diabetes Receiving Intensive Insulin Therapy

Type 2 Diabetes Mellitus

China
Nanjing First Hospital, Nanjing Medical University

Active, not recruiting

Comparing the Efficacy of Mulberry Twig Alkaloid Tablet and Canagliflozin in Patients With Type 2 Diabetes

Type 2 Diabetes Mellitus

China
Sanofi

Completed

Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (FRC) Versus GLP-1 Receptor Agonist in Patients With Type 2 Diabetes, With a FRC Extension Period (LixiLan-G)

Type 2 Diabetes Mellitus

Estonia, Italy, Israel, United States, Canada, Germany, Romania, Slovakia, Spain
Yonsei University

Completed

Effect of Sodium Glucose Co-transporter 2 Inhibitor on Inflammatory Cytokine in Type 2 Diabetes

Type2 Diabetes Mellitus

Korea, Republic of
Mitsubishi Tanabe Pharma Corporation

Completed

Long-Term Safety Study of MT-2412 in Japanese Patients With Type 2 Diabetes

Type 2 Diabetes Mellitus

Japan
Mitsubishi Tanabe Pharma Corporation

Completed

Confirmatory Study of MT-2412 in Japanese Patients With Type 2 Diabetes (Add-on Study of Canagliflozin)

Type 2 Diabetes Mellitus

Japan
AstraZeneca Turkey
Optimum Contract Research Organization, Turkey

Completed

Dapagliflozin in Type 2 Diabetes Patients, a Retrospective Cohort Study From Turkey (DAPA-TURK)

Type 2 Diabetes Mellitus

Turkey
University of Palermo
AstraZeneca; University of Catania

Unknown

Dapagliflozin, Cardio-Metabolic Risk Factors and Type-2 Diabetes

Type 2 Diabetes Mellitus

Italy
AstraZeneca
Astra Zeneca, Bristol-Myers Squibb

Completed

Effects of Dapagliflozin on Kidney Function (Glomerular Filtration Rate) in Subjects With Type 2 Diabetes

Type 2 Diabetes Mellitus

United States, Netherlands, Canada
Novartis Pharmaceuticals

Completed

Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) Assessment of LIK066 in Healthy Subjects and in Patients With Type 2 Diabetes Mellitus (T2DM)

Type 2 Diabetes Mellitus (T2DM)

United States
AstraZeneca
Bristol-Myers Squibb

Completed

Bioavailability Study of Fixed Dose Combination (FDC) Formulations of Dapagliflozin and Metformin XR Versus Individual Component Coadministered to Healthy Subjects in a Fasted State

Type 2 Diabetes Mellitus (T2DM)

United States
Merck Sharp & Dohme LLC
Pfizer

Completed

A Radiolabeled Mass Balance Study of [14C]-Ertugliflozin (PF04971729, MK-8835) In Healthy Male Participants (MK-8835-038)

Type 2 Diabetes Mellitus (T2DM)
Seoul National University Bundang Hospital
Astellas Pharma Korea, Inc.

Completed

Efficacy of Ipragliflozin Compared With Sitagliptin in Uncontrolled Type 2 Diabetes With Sulfonylurea and Metformin

Type 2 Diabetes Mellitus

Korea, Republic of
Sanofi

Completed

Evaluation of Insulin Glargine/Lixisenatide Fixed Ratio Combination in Patients With Type 2 Diabetes Insufficiently Controlled With Oral Antidiabetic Drug(s) (Lixilan-O-AP)

Type 2 Diabetes Mellitus

China, Korea, Republic of, Malaysia, Taiwan
Population Health Research Institute
AstraZeneca

Completed

Remission Evaluation of a Metabolic Intervention in Type 2 Diabetes With Forxiga

Type 2 Diabetes Mellitus

Canada
Eli Lilly and Company

Completed

A Study of LY900014 Compared to Insulin Lispro in Participants With Type 2 Diabetes (PRONTO-T2D)

Type 2 Diabetes Mellitus

United States, Hungary, Puerto Rico, Spain, Australia, Korea, Republic of, Mexico, Japan, Germany, Russian Federation, Taiwan, Slovakia, Argentina, Czechia, India, Italy
Astellas Pharma Inc

Completed

A Study to Assess the Efficacy and Safety of ASP1941 in Japanese Type 2 Diabetes Patients

Type 2 Diabetes Mellitus

Japan
AstraZeneca

Completed

A 24-week Open-Label, Phase 3b Trial With a 28-week Extension to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin Compared to Insulin Glargine in Subjects withType 2 Diabetes Who Have Glycemic Control on Metformin

Type 2 Diabetes Mellitus

United States, Poland, Mexico, Hungary, Spain, Romania, South Africa, Denmark, Czechia, Sweden
AstraZeneca
Bristol-Myers Squibb

Completed

Study of Dapagliflozin in Combination With Metformin XR to Initiate the Treatment of Type 2 Diabetes

Type 2 Diabetes Mellitus

Korea, Republic of, United States, Mexico, India, Puerto Rico, Russian Federation
AstraZeneca

Completed

Phase IV Study With a 36-week Extension Period to Evaluate the Efficacy and Safety of Dapagliflozin Therapy When Added to the Therapy of Japanese Patients With Type 2 Diabetes With Inadequate Glycemic Control on Insulin.

Type 2 Diabetes Mellitus

Japan
Lexicon Pharmaceuticals

Completed

Safety and Efficacy of LX4211 With Metformin in Type 2 Diabetes Patients With Inadequate Glycemic Control on Metformin

Type 2 Diabetes Mellitus

United States
University Hospital Tuebingen

Withdrawn

Empagliflozin Effect on Glucose Toxicity

Type2 Diabetes Mellitus

Germany
University of Liverpool
AstraZeneca; Clinical Practice Research Datalink

Active, not recruiting

A Pragmatic Randomized Trial to Evaluate the Comparative Effectiveness Between Dapagliflozin and Standard of Care in Type 2 Diabetes Patients (DECIDE)

Type 2 Diabetes Mellitus

United Kingdom
Peking Union Medical College Hospital
Chinese Academy of Sciences

Unknown

Response of Gut Microbiota in Type 2 Diabetes to Hypoglycemic Agents

Type2 Diabetes Mellitus

China
Merck Sharp & Dohme LLC
Pfizer

Completed

A Study to Evaluate the Efficacy and Safety of Ertugliflozin in Asian Participants With Type 2 Diabetes and Inadequate Glycemic Control on Metformin Monotherapy (MK-8835-012)

Type 2 Diabetes Mellitus
Mitsubishi Tanabe Pharma Corporation

Completed

Confirmatory Study of MT-2412 in Japanese Patients With Type 2 Diabetes (Add-on Study of Teneligliptin)

Type 2 Diabetes Mellitus

Japan
BHV Pharma
Integrium

Completed

Safety and Efficacy of Biphasic Remogliflozin Etabonate in the Treatment of Type 2 Diabetes (BRID)

Diabetes Mellitus, Type 2 | Type 2 Diabetes Mellitus

United States
AstraZeneca
Bristol-Myers Squibb

Completed

Safety and Efficacy of Dapagliflozin as Monotherapy in Subjects With Type 2 Diabetes

Type 2 Diabetes Mellitus

United States, Canada, Mexico, India, Puerto Rico, Russian Federation, South Africa
Mitsubishi Tanabe Pharma Corporation

Completed

Efficacy and Safety Study of TA-7284 in Patients With Type 2 Diabetes

Type 2 Diabetes Mellitus

Japan
Novartis Pharmaceuticals

Withdrawn

Dose-finding Study of LIK066 Compared With Placebo or Sitagliptin to Evaluate Change in HbA1c in Patients With Diabetes

Type 2 Diabetes Mellitus
Novartis

Completed

Phase 4 Study in the Elderly Patients With T2DM (GLYCEMIA)

Type 2 Diabetes Mellitus | Elderly

France
Matteo Cameli
Fondazione Toscana G. Monasterio, Pisa; Cardiology and Cardiovascular Pathophysiology... and other collaborators

Recruiting

Deformation Imaging by Strain in Chronic Heart Failure Over Gliflozins: an Echocardiographic Register on Sodium-GLucose coTransporter-2 Inhibitors (DISCOVERSGLT2i)

Heart Failure With Reduced Ejection Fraction | Sodium-GLucose coTransporter-2 Inhibitors

Italy
HighTide Biopharma Pty Ltd
Shenzhen HighTide Biopharmaceutical Ltd.

Recruiting

Effects of Berberine Ursodeoxycholate (HTD1801) Versus Dapagliflozin in Patients With Type 2 Diabetes Inadequately Controlled With Metformin

T2DM (Type 2 Diabetes Mellitus)

China
Daewoong Pharmaceutical Co. LTD.

Completed

The Efficacy and Safety of DWP16001 in Combination With Metformin in Patients With Type 2 Diabetes. (ENHANCE-M)

T2DM (Type 2 Diabetes Mellitus)

Korea, Republic of
University Hospital Tuebingen

Withdrawn

Dapagliflozin Effect on Erythropoiesis and Physical Fitness

Type 2 Diabetes Mellitus (T2DM)

Germany
Sanofi Pasteur, a Sanofi Company

Completed

Safety Surveillance of VaxigripTetra® and Efluelda® Influenza Vaccines in Europe During the Influenza Season 2022/23

Influenza (Healthy Volunteers)

Germany, Finland
Seoul National University Bundang Hospital

Recruiting

Comparison of Dapagliflozin, Lobeglitazone, and Its Combination in Efficacy and Safety (Location-F)

Diabetes Type 2

Korea, Republic of
Eastern Mediterranean University

Not yet recruiting

The Effect of Health Education and Yoga on Menopause Symptoms and Quality of Life According to Pender's Model

Quality of Life | Health Education | Yoga | Menopause Symptoms

Cyprus
Eastern Mediterranean University

Not yet recruiting

Effect of Acupressure on Pain, Anxiety and Vital Signs in Patients With Coronary Angiography

Pain | Anxiety | Coronary Angiography | Vital Signs

Cyprus
RWTH Aachen University
Boehringer Ingelheim

Completed

Empagliflozin as a Modulator of Systemic Vascular Resistance and Cardiac Output in Patients With Type 2 Diabetes (EMPA)

Diabetes Mellitus Type 2 (T2DM)

Germany
Boehringer Ingelheim

Completed

A Study Using Swedish Registries to Find Out How Many People With Type 2 Diabetes Had Cardiovascular Disease and Started Treatment With Empagliflozin Between 2015 and 2017

Type 2 Diabetes Mellitus

Sweden
AstraZeneca

Completed

A Multi-Center, Randomized, Double-Blind, Phase III Trial to Evaluate the Safety and Efficacy of Saxagliptin Co-administered With Dapagliflozin Compared to Saxagliptin or Dapagliflozin All Given as add-on Therapy to Metformin in Subject With Type 2 Diabetes

Type 2 Diabetes Mellitus | Inadequate Glycaemic Control

United States, Canada, Czechia, Germany, Russian Federation, Mexico
AstraZeneca

Completed

Efficacy and Safety of Dapagliflozin and Dapagliflozin Plus Saxagliptin in Combination With Metformin in Type 2 Diabetes Patients Compared With Sulphonylurea

Type 2 Diabetes Mellitus | Inadequate Glycaemic Control

Germany, Slovakia, Czechia, Hungary, Poland
AstraZeneca
Astra Zeneca, Bristol-Myers Squibb

Completed

Effects of Dapagliflozin on Insulin Resistance and Insulin Secretion in Subjects With Type 2 Diabetes

Type 2 Diabetes Mellitus

United States
AstraZeneca
Bristol-Myers Squibb

Completed

Evaluation of Safety and Efficacy of Dapagliflozin in Subjects With Type 2 Diabetes Who Have Inadequate Glycaemic Control on Background Combination of Metformin and Sulfonylurea

Type 2 Diabetes Mellitus | Inadequate Glycaemic Control | High HbA1c Level

Czech Republic, Poland, Spain, Germany, Canada, Slovakia
Theravance Biopharma

Terminated

Efficacy & Safety of TD-1473 in Ulcerative Colitis (RHEA)

Ulcerative Colitis (UC)

United States, Australia, Bulgaria, Canada, France, Georgia, Germany, Greece, Hungary, Israel, Italy, Japan, Korea, Republic of, Poland, Portugal, Romania, Serbia, Slovakia, South Africa, Spain, Taiwan, Ukraine
Biosplice Therapeutics, Inc.

Completed

A Study Utilizing Patient-Reported and Radiographic Outcomes and Evaluating the Safety and Efficacy of Lorecivivint (SM04690) for the Treatment of Moderately to Severely Symptomatic Knee Osteoarthritis (STRIDES-X-ray)

Knee Osteoarthritis

United States
Kaiser Permanente
Patient-Centered Outcomes Research Institute; Henry Ford Health System; HealthPartners... and other collaborators

Recruiting

Comparison of Type 2 Diabetes Pharmacotherapy Regimens (ON TARGET DM)

Cardiovascular Diseases | Type 2 Diabetes Mellitus

United States
Kirsehir Ahi Evran Universitesi

Not yet recruiting

Supportive Care Training Given to Mothers of Babies With Infants Colic

Infantile Colic | Mothers

Turkey

3

Subscribe